Analysts bearish on Surgery Partners — 4 insights

After Zacks Investment Research downgraded Surgery Partners from a hold to a sell, other analysts are following suit, Transcript Daily reports.

Advertisement

Here’s what you should know:

1. BidaskClub assigned Surgery Partners a sell rating in its latest research note.

2. Stifel Nicolaus assigned the company a hold rating, but dropped its price objective from $19 a share to $18 a share.

3. On average analysts project a price target of $21.40 for Surgery Partners.

4. Surgery Partners closed Jan. 24 at $21.38.

More articles on transactions/valuations:
Concord Orthopaedics’ ASC plans up in the air due to rezoning concerns: 4 takeaways
Compass Surgical Partners opens multispecialty ASC & more — 5 ASC company key notes
Compass Surgical Partners opens freestanding Florida ASC: 4 key points

Advertisement

Next Up in ASC Transactions & Valuation Issues

Advertisement

Comments are closed.